Top

Published in:

01-11-2006 | Review Article

The puzzle of overactive bladder: controversies, inconsistencies, and insights

Author: Roger R. Dmochowski

Published in: International Urogynecology Journal | Issue 6/2006

Abstract

Overactive bladder (OAB) affects millions of individuals and may severely impair the quality of life of those affected. The contribution of human behavior to manifestations of this symptom complex remains poorly understood. Continued evolution of our understanding of the pathophysiology of OAB has identified contributory mechanisms, which in turn may open new therapeutic avenues. Recent improvements in drug delivery systems represent advances in the management of OAB. However, more complete symptom control with greater tolerability is desirable; this awaits the development of agents specific for newly emerging and as yet unidentified pathophysiologic pathways. Importantly, as understanding of outcomes assessment in OAB matures, refined assessments of disease severity, response to intervention, and patient preference should be possible.

Wein AJ, Rovner ES (2002) Definition and epidemiology of overactive bladder. Urology 60:7–12PubMedCrossRef

Horrocks S, Somerset M, Stoddart H, Peters TJ (2004) What prevents older people from seeking treatment for urinary incontinence? A qualitative exploration of barriers to the use of community continence services. Fam Pract 21:689–696PubMedCrossRef

Weidner AC, Myers ER, Visco AG, Cundiff GW, Bump RC (2001) Which women with stress incontinence require urodynamic evaluation? Am J Obstet Gynecol 184:20–27PubMedCrossRef

Andersson K-E (2004) Antimuscarinics for treatment of overactive bladder. Lancet 3:46–53CrossRef

Stach-Lempinen B, Kirkinen P, Laippala P, Metsunoja R, Kujansuu E (2004) Do objective urodynamic or clinical findings determine impact of urinary incontinence or its treatment on quality of life? Urology 63:67–72PubMedCrossRef

Malone-Lee J, Henshaw DJE, Cummings K (2003) Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response. BJU Int 92:415–417PubMedCrossRef

Burgio KL, Locher JL, Goode PS, et al (1998) Behavioral vs drug treatment for urge urinary incontinence in older women. JAMA 280:1995–2000PubMedCrossRef

Mattiasson A, Blaakaer J, Hoye K, Wein AJ, and the Tolterodine Study Group (2003) Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int 91:54–60PubMedCrossRef

Abrams P, Cardozo L, Fall M et al (2003) The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society. Urology 61:37–49PubMedCrossRef

10.

Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327–336PubMed

11.

Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760–766PubMedCrossRef

12.

Van Der Vaart CH, De Leeuw JRJ, Roovers JPWR, Heintz APM (2002) The effect of urinary incontinence and overactive bladder symptoms on quality of life in young women. BJU Int 90:544–549PubMedCrossRef

13.

Corcos J, Beaulieu S, Donovan J, Naughton M, Gotoh M, and Members of the Symptom and Quality of Life Assessment Committee of the First International Consultation on Incontinence (2002) Quality of life assessment in men and women with urinary incontinence. J Urol 168:896–905PubMedCrossRef

14.

Wagner TH, Hu TW, Bentkover J et al (2002) Health-related consequences of overactive bladder. Am J Manag Care 8:S598–607PubMed

15.

Kelleher CJ (2005) Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 95:81–85PubMedCrossRef

16.

Fultz NH, Herzog AR (2001) Self-reported social and emotional impact of urinary incontinence. J Am Geriatr Soc 49:892–899PubMedCrossRef

17.

Davila GW, Neimark M (2002) The overactive bladder: prevalence and effects on quality of life. Clin Obstet Gynecol 45:173–181PubMedCrossRef

18.

Liberman JN, Hunt TL, Stewart WF et al (2001) Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 57:1044–1050PubMedCrossRef

19.

Scarpero HM, Fiske J, Xue X, Nitti VW (2003) American Urological Association Symptom Index for lower urinary tract symptoms in women: correlation with degree of bother and impact on quality of life. Urology 61:1118–1122PubMedCrossRef

20.

Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J et al (2002) Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 11:563–574PubMedCrossRef

21.

Coyne KS, Zhou Z, Bhattacharyya SK, Thompson CL, Dhawan R, Versi E (2003) The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample of the USA. BJU Int 92:948–954PubMedCrossRef

22.

Fiske J, Scarpero HM, Xue X, Nitti VW (2004) Degree of bother caused by nocturia in women. Neurourol Urodynam 23:130–133CrossRef

23.

Brubaker L (2004) Urgency: the cornerstone symptom of overactive bladder. Urology 64:12–16PubMedCrossRef

24.

Chiaffarino F, Parazzini F, Lavezzari M, Giambanco V, on Behalf of Gruppo Interdisciplinare di Studio Incontinenza Urinaria (2003) Impact of urinary incontinence and overactive bladder on quality of life. Eur Urol 43:535–538PubMedCrossRef

25.

Goepel M, Hoffmann JA, Piro M, Rubben H, Michel MC (2002) Prevalence and physician awareness of symptoms of urinary bladder dysfunction. Eur Urol 41:234–239PubMedCrossRef

26.

Ricci JA, Baggish JS, Hunt TL et al (2001) Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder. Clin Ther 23:1245–1259PubMedCrossRef

27.

Hannestad YS, Rortveit G, Sandvik H, Hunskaar S (2000) A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. J Clin Epidemiol 53:1150–1157PubMedCrossRef

28.

Diokno AC, Burgio K, Fultz NH, Kinchen KS, Obenchain R, Bump RC (2004) Medical and self-care practices reported by women with urinary incontinence. Am J Manag Care 10:69–78PubMed

29.

Shaw C, Tansey R, Jackson C, Hyde C, Allan R (2001) Barriers to help seeking in people with urinary symptoms. Fam Pract 18:48–52PubMedCrossRef

30.

Locher JL, Burgio KL, Goode PS, Roth DL, Rodriguez E (2002) Effects of age and causal attribution to aging on health-related behaviors associated with urinary incontinence in older women. Gerontologist 42:515–521PubMed

31.

Steers WD (2002) Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol 4:S7–18PubMed

32.

Flisser AJ, Walmsley K, Blaivas JG (2003) Urodynamic classification of patients with symptoms of overactive bladder. J Urol 169:529–534PubMedCrossRef

33.

Yokoyama O, Komatsu K, Ishiura Y et al (2002) Overactive bladder-experimental aspects. Scand J Urol Nephrol (Suppl) 210:59–64CrossRef

34.

Espey MJ, Du H-J, Downie JW (1998) Serotonergic modulation of spinal ascending activity and sacral reflex activity evoked by pelvic nerve stimulation in cats. Brain Res 798:101–108PubMedCrossRef

35.

de Groat WC (2002) Influence of central serotonergic mechanisms on lower urinary tract function. Urology 59(5 Suppl 1):30–36PubMed

36.

Fowler CJ (2002) Bladder afferents and their role in the overactive bladder. Urology 59(5 Suppl 1):37–42PubMedCrossRef

37.

De Ridder D, Baert L (2000) Vanilloids and the overactive bladder. BJU Int 86:172–180PubMedCrossRef

38.

Ahlberg J, Edlund C, Wikkelsö C, Rosengren L, Fall M (2002) Neurological signs are common in patients with urodynamically verified “idiopathic” bladder overactivity. Neurourol Urodynam 21:65–70CrossRef

39.

Brading AF (1997) A myogenic basis for the overactive bladder. Urology 50:57–67PubMedCrossRef

40.

Haferkamp A, Dorsam J, Resnick NM, Yalla SV, Elbadawi A (2003) Structural basis of neurogenic bladder dysfunction. II. Myogenic basis of detrusor hyperreflexia. J Urol 169:547–554PubMedCrossRef

41.

Yoshida M, Miyamae K, Iwashita H, Otani M, Inadome A (2004) Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology 63(Suppl 3A):17–23PubMedCrossRef

42.

O’Reilly BA, Kosaka AH, Knight GF et al (2002) P2X receptors and their role in female idiopathic detrusor instability. J Urol 167:157–164PubMedCrossRef

43.

Moore KH, Ray FR, Barden JA (2001) Loss of purinergic P2X(3) and P2X(5) receptor innervation in human detrusor from adults with urge incontinence. J Neurosci 21:1–6

44.

Messelink EJ (1999) The overactive bladder and the role of the pelvic floor muscles. BJU Int 83(Suppl 2):31–35PubMedCrossRef

45.

Teleman PM, Lidfelt J, Nerbrand C, Samsioe G, Mattiasson A, WHILA study group (2004) Overactive bladder: prevalence, risk factors, and relation to stress incontinence in middle-aged women. BJOG 111:600–604PubMed

46.

Bump RC, Norton PA, Zinner NR, Yalcin I, Duloxetine Urinary Incontinence Study Group (2003) Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response. Obstet Gynecol 102:76–83PubMedCrossRef

47.

Colli E, Artibani W, Goka J, Parazzini F, Wein AJ (2003) Are urodynamic tests useful tools for the initial conservative management of non-neurogenic urinary incontinence? A review of the literature. Eur Urol 43:63–69PubMedCrossRef

48.

Glazener CMA, Lapitan MC (2002) Urodynamic investigations for management of urinary incontinence in adults. Cochrane Database Syst Rev 3:CD003195PubMed

49.

Arya LA, Myers DL, Jackson ND (2000) Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstet Gynecol 96:85–89PubMedCrossRef

50.

Hannestad YS, Rortveit G, Daltveit AK, Hunskaar S (2003) Are smoking and other lifestyle factors associated with female urinary incontinence? The Norwegian EPINCONT Study. Br J Obstet Gynecol 110:247–254

51.

Dasgupta J, Elliot R, Tincello D (2004) Do artificial sweeteners affect bladder contraction? Presented at the 34th Annual Meeting of the International Continence Society, Paris, France, August 25, 2004

52.

Fantl J, Newman D, Colling J et al (1996) Urinary incontinence in adults: acute and chronic management. Clinical Practice Guideline Number 2 (1996 Update) AHCPR Publication No. 96-0682, March 1996. Available at: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat6.chapter.9995

53.

Burgio KL, Goode PS, Locher JL et al (2002) Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA 288:2293–2299PubMedCrossRef

54.

Berghmans LC, Hendriks HJ, De Bie RA, van Waalwijk van Doorn ES, Bo K, van Kerrebroeck PE (2000) Conservative treatment of urge urinary incontinence in women: a systematic review of randomized clinical trials. BJU Int 85:254–263PubMedCrossRef

55.

Eustice S, Roe B, Paterson J (2000) Prompted voiding for the management of urinary incontinence in adults. Cochrane Database Syst Rev 2:CD002113PubMed

56.

Roe B, Williams K, Palmer M (2000) Bladder training for urinary incontinence in adults. Cochrane Database Syst Rev 2:CD001308PubMed

57.

Bo K, Kvarstein B, Nygaard I (2005) Lower urinary tract symptoms and pelvic floor muscle exercise adherence after 15 years. Obstet Gynecol 105:999–1005PubMed

58.

Burgio KL, Locher JL, Goode PS (2000) Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 48:370–374PubMed

59.

Haeusler G, Leitich H, van Trotsenburg M, Kaider A, Tempfer CB (2002) Drug therapy of urinary urge incontinence: a systematic review. Obstet Gynecol 100:1003–1016PubMedCrossRef

60.

Fetscher C, Fleichman M, Schmidt M, Krege S, Michel MC (2002) M(3) muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol 136:641–643PubMedCrossRef

61.

Andersson KE, Yoshida M (2003) Antimuscarinics and the overactive detrusor—which is the main mechanism of action? Eur Urol 43:1–5PubMedCrossRef

62.

Lawrence M, Guay DR, Benson SR, Anderson MJ (2000) Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy 20:470–475PubMedCrossRef

63.

Scarpero HM, Dmochowski RR (2003) Muscarinic receptors: what we know. Curr Urol Rep 4:421–428PubMed

64.

Haab F, Stewart L, Dwyer P (2004) Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 45:420–429PubMedCrossRef

65.

Zinner N, Harnett M, Sabounjian L, Sandage B Jr, Dmochowski R, Staskin D (2005) The overactive bladder symptom composite score: a composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder. J Urol 173:1639–1643PubMedCrossRef

66.

Diokno A, Sand P, Peters K, Kell S (2003) A prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine: results of the OPERA trial. Mayo Clin Proc 78:687–695PubMed

67.

Cardozo L, Lisec M, Millard R et al (2004) Randomized, double-blind placebo-controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172:1919–1924PubMedCrossRef

68.

Garely AD, Burrows LJ (2002) Current pharmacotherapeutic strategies for overactive bladder. Expert Opin Pharmacother 3:827–833PubMedCrossRef

69.

Goldenberg MM (1999) An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. Clin Ther 21:634–642PubMedCrossRef

70.

Appell RA, Sand P, Dmochowski R et al (2001) Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc 76:358–363PubMed

71.

Sussman D, Garely A (2002) Treatment of overactive bladder with once-daily extended release tolterodine or oxybutynin: the Antimuscarinic Clinical Effectiveness Trial (ACET). Curr Med Res Opin 18:177–184PubMedCrossRef

72.

Bang LM, Easthope SE, Perry CM (2003) Transdermal oxybutynin for overactive bladder. Drugs Aging 20:857–864PubMedCrossRef

73.

Dmochowski RR, Davila GW, Zinner NR et al, for The Transdermal Oxybutynin Study Group (2002) Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 168:580–586PubMedCrossRef

74.

Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW, for the Transdermal Oxybutynin Study Group (2003) Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 62:237–242PubMedCrossRef

75.

Zinner N, Gittelman M, Harris R, Susset J, Kanellos A, Auerbach S, for The Trospium Study Group (2004) Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 171:2311–2315PubMedCrossRef

76.

Schroder S, Jetter A, Zaigler M et al (2004) Absorption pattern of trospium chloride along the human gastrointestinal tract assessed using local enteral administration. Int J Clin Pharmacol Ther 42:543–549PubMed

77.

Ohtake A, Ukai M, Hatanaka T et al (2004) In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 492:243–250PubMedCrossRef

78.

Oki T, Sato S, Miyata K, Yamada S (2005) Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice. Br J Pharmacol 145:219–227PubMedCrossRef

79.

Chapple CR, Rechberger T, Al-Shukri S et al, on behalf of the YM-905 Study Group (2004) Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93:303–310PubMedCrossRef

80.

Dmochowski R (2004) Interventions and outcomes: what is important (and what is not)? J Urol 172:8–9PubMedCrossRef

81.

Diokno A, Sand P, Labasky R et al (2002) Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study. Int Urol Nephrol 34:43–49PubMedCrossRef

82.

Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM (2005) Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 95:81–85PubMedCrossRef

83.

Haab F, Cardozo L, Chapple C, Ridder AM, for the Solifenacin Study Group (2005) Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 48:464–470

84.

Ramsey SD (2000) Suboptimal medical therapy in COPD: exploring the causes and consequences. Chest 117:33S–37SPubMedCrossRef

85.

Loghman-Adham M (2003) Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care 9:155–171PubMed

86.

Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z (2005) Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 11:S121–S129PubMed

87.

Kelleher CJ, Kreder KJ, Pleil AM, Burgess SM, Reese PR (2002) Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 8:S616–S630PubMed

88.

MacDiarmid SA, Anderson RU, Armstrong RB, Dmochowski RR (2005) Efficacy and safety of extended-release oxybutynin in the treatment of urge incontinence: an analysis of data from three flexible-dosing studies. J Urol (in press)

89.

Steers W, Corcos J, Foote J, Kralidis G (2005) An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int 95:580–586PubMedCrossRef

90.

Sellers DJ, Chapple CR, Chess-Williams R (2001) Potential therapeutic targets for treatment of the overactive bladder. World J Urol 19:307–311PubMedCrossRef

91.

Yoshimura N, Chancellor MB (2002) Current and future pharmacological treatment for overactive bladder. J Urol 168:1897–1913PubMedCrossRef

92.

Cannon TW, Chancellor MB (2002) Pharmacotherapy of the overactive bladder and advances in drug delivery. Clin Obstet Gynecol 45:205–217PubMedCrossRef

93.

Kim DY, Chancellor MB (2000) Intravesical neuromodulatory drugs: capsaicin and resiniferatoxin to treat the overactive bladder. J Endourol 14:97–103PubMedCrossRef

94.

Smith CP, Chancellor MB (2004) Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol 171:2128–2137PubMedCrossRef

Title: The puzzle of overactive bladder: controversies, inconsistencies, and insights
Author: Roger R. Dmochowski
Publication date: 01-11-2006
Publisher: Springer-Verlag
Published in: International Urogynecology Journal / Issue 6/2006
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-005-0032-3

2024 ASCO Annual Meeting

Springer Medicine

The puzzle of overactive bladder: controversies, inconsistencies, and insights

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2006

Assessment of voluntary pelvic floor muscle contraction in continent and incontinent women using transperineal ultrasound, manual muscle testing and vaginal squeeze pressure measurements

Prediction of successful voiding immediately after outpatient mid-urethral sling

Sexual function in patients presenting to a urogynecology practice

Urinary retention following tension-free vaginal tape successfully treated by sacral neuromodulation

Humanitarian ventures or ‘fistula tourism?’: the ethical perils of pelvic surgery in the developing world

Incidence of stress urinary incontinence among women in Turkey